{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:21:56Z","timestamp":1772983316742,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The anticoagulant application is an effective treatment modality for cardiovascular diseases such as coronary heart disease, unstable angina pectoris, and myocardial infarction. In this study, the antithrombotic effect of recombinant neorudin (EPR\u2010hirudin, EH) was evaluated using a canine model of coronary artery thrombosis. A canine model with platelet thrombosis in the left circumferent branch of the coronary artery was designed using Folt's method, and the anti\u2010thrombus activity of EH was investigated. Femoral administration of EH intravenously had a significant dose\u2010dependent inhibitory effect on canine coronary artery thrombosis and the effective rates were 66.7% (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a0.05), 83.3% (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a0.05), and 100% (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a0.01) after injection of 0.3, 1.0, and 3.0\u00a0mg\/kg EH, respectively. Furthermore, EH demonstrated lower bleeding, with shorter bleeding time and less bleeding loss than low molecular weight heparin (LMWH). Under the similar effect intensity of EH and LMWH (85\u00a0IU\/kg), the bleeding time of the EH group at 30\u00a0min was shorter, and the blood loss at 30\u2013120\u00a0min was less than that of LMWH (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a0.05 and\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a0.05\u2013.001, respectively). EH had a significant dose\u2010dependent inhibitory effect in the dose range of 0.3\u20133.0\u00a0mg\/kg on the coronary artery thrombosis and lower bleeding side effects than LMWH with a similar antithrombosis effect.\n                  <\/jats:p>","DOI":"10.1002\/prp2.956","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T01:55:24Z","timestamp":1651629324000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibitory role of recombinant neorudin on canine coronary artery thrombosis"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-8727","authenticated-orcid":false,"given":"Yu\u2010bin","family":"Liu","sequence":"first","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing\u2010chen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuan\u2010you","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Pharmacodynamic Research Tianjin Institute of Pharmaceutical Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu\u2010tse","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u2010de","family":"Jin","sequence":"additional","affiliation":[{"name":"Beijing Institute of Radiation Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"582","article-title":"Report on cardiovascular health and diseases burden in China: an updated summary of 2020","volume":"19","author":"Hu SS","year":"2021","journal-title":"Chin Circ J"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.01.019"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066616656333"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000115"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.64S"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1062-0303(97)90057-1"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32835e4219"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-019-0347-0"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199512040-00002"},{"issue":"5","key":"e_1_2_11_11_1","first-page":"819","article-title":"The direct thrombin inhibitor hirudin","volume":"99","author":"Greinacher A","year":"2008","journal-title":"Thromb Haemost"},{"key":"e_1_2_11_12_1","unstructured":"WuZ YuA ZhangC et al.Preparation of low bleeding anticoagulant fusion protein and its use. US Patent 20100113345A1. PCT No. PCT\/CN2007\/03526. WO 2008\/071081 A1. Filed December 11 2007; issued May 6 2010."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-07-0453"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.05.048"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199102000-00021"},{"issue":"6","key":"e_1_2_11_16_1","first-page":"IV3","article-title":"An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis","volume":"83","author":"Folts J","year":"1991","journal-title":"Circulation"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568006023337772"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.4.1182"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000258"},{"issue":"5","key":"e_1_2_11_20_1","first-page":"243","article-title":"Syndrome coronarien aigu [Acute coronary syndrome]","volume":"73","author":"Gach O","year":"2018","journal-title":"Rev Med Liege"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2048872614527008"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.05.007"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13194"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002456"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1718888"},{"issue":"2","key":"e_1_2_11_26_1","first-page":"111","article-title":"Anti\u2010thrombus activity of a novel anti\u2010thrombus protein EPR\u2010hirudin","volume":"48","author":"Wang W","year":"2013","journal-title":"Chin Pharm J"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.956","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T09:08:13Z","timestamp":1772960893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/prp2.956"],"URL":"https:\/\/doi.org\/10.1002\/prp2.956","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"2021-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00956"}}